Leukemia, Myelomonocytic, Chronic: all 340 studies

Page 2 of 4. Open to participants first (69), then studies with results posted, then the rest; newest registration first within each.

• WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT02666950Phase 2Results posted
• An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)CompletedNCT02610777Phase 2Results posted
• Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT02566304Phase 2Results posted
• Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft MalignanciesCompletedNCT02556931Phase 2Results posted
• Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT02397720Phase 2Results posted
• A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML PatientsCompletedNCT02367456Phase 1Results posted
• Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF)CompletedNCT02268253Phase 1/2Results posted
• Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic LeukemiaCompletedNCT02201329Phase 1Results posted
• Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative NeoplasmCompletedNCT02121418Not applicableResults posted
• Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMMLTerminatedNCT01957644Phase 1Results posted
• Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid LeukemiaStatus unknownNCT01894477Phase 2Results posted
• Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT01892371Phase 1/2Results posted
• Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic LeukemiaActive, not recruitingNCT01885689Phase 2Results posted
• Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity AssayCompletedNCT01872819Not applicableResults posted
• Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)CompletedNCT01842646Phase 2Results posted
• Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromesCompletedNCT01831232Not applicableResults posted
• Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic LeukemiaCompletedNCT01824693Phase 2Results posted
• Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid MalignanciesCompletedNCT01823198Phase 1/2Results posted
• Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell TransplantCompletedNCT01812252Phase 2Results posted
• Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological MalignanciesCompletedNCT01789255Phase 2Results posted
• A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of RuxolitinibCompletedNCT01776723Phase 1/2Results posted
• GVAX vs. Placebo for MDS/AML After Allo HSCTTerminatedNCT01773395Phase 2Results posted
• Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic AnemiaCompletedNCT01772420Phase 2Results posted
• Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic MalignanciesCompletedNCT01760655Phase 2Results posted
• Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)CompletedNCT01736683Phase 2Results posted
• Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01664897Phase 2Results posted
• Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous LeukemiaTerminatedNCT01620216Phase 2Results posted
• Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT01529827Phase 2Results posted
• Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic LeukemiaActive, not recruitingNCT01522976Phase 2Results posted
• Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological MalignanciesCompletedNCT01427881Phase 2Results posted
• A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological MalignanciesCompletedNCT01384513Phase 2Results posted
• A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic LeukemiaCompletedNCT01350947Phase 2Results posted
• Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow TransplantationCompletedNCT01338987Phase 2Results posted
• Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid LeukemiaCompletedNCT01307579Phase 3Results posted
• Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell TransplantCompletedNCT01305200Phase 3Results posted
• Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDSCompletedNCT01300572Phase 1Results posted
• Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic CancerCompletedNCT01233921Not applicableResults posted
• Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic SyndromeCompletedNCT01165996Phase 1/2Results posted
• Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron OverloadTerminatedNCT01159067Phase 2Results posted
• Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative NeoplasmCompletedNCT01101880Phase 2Results posted
• Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT01093586Phase 2Results posted
• Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell TransplantCompletedNCT01083706Phase 2Results posted
• A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).CompletedNCT00946647Phase 1/2Results posted
• Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic LeukemiaCompletedNCT00860574Phase 2Results posted
• Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure DisordersCompletedNCT00856388Not applicableResults posted
• Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and AnemiaActive, not recruitingNCT00843882Phase 3Results posted
• Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell TransplantCompletedNCT00795769Phase 2Results posted
• Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic LeukemiaTerminatedNCT00708721Phase 1/2Results posted
• Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid LeukemiaCompletedNCT00666588Phase 2Results posted
• Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic SyndromeTerminatedNCT00589316Phase 1Results posted
• Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other DisordersActive, not recruitingNCT00544115Phase 2Results posted
• Sorafenib in Myelodysplastic SyndromeTerminatedNCT00510289Phase 2Results posted
• Aflibercept in Treating Patients With Myelodysplastic SyndromesTerminatedNCT00509249Phase 2Results posted
• MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic LeukemiaCompletedNCT00462605Phase 2Results posted
• Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic LeukemiaCompletedNCT00451048Phase 2Results posted
• Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell TransplantCompletedNCT00408681Not applicableResults posted
• Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative DisordersCompletedNCT00397813Phase 2Results posted
• Sunitinib in Treating Patients With Idiopathic MyelofibrosisTerminatedNCT00387426Phase 2Results posted
• 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous LeukemiaCompletedNCT00381550Phase 2Results posted
• Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid LeukemiaCompletedNCT00313586Phase 2Results posted
• Oral Clofarabine Study in Patients With Myelodysplastic SyndromeCompletedNCT00299156Phase 2Results posted
• Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)CompletedNCT00255346Phase 2Results posted
• Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)CompletedNCT00167219Phase 1/2Results posted
• Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic SyndromeTerminatedNCT00119366Phase 2Results posted
• Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00118352Phase 2Results posted
• Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine FailureTerminatedNCT00113321Phase 2Results posted
• Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without CancerCompletedNCT00112593Not applicableResults posted
• Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid LeukemiaCompletedNCT00096122Phase 1/2Results posted
• Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS)CompletedNCT00067808Phase 2Results posted
• Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib MesylateCompletedNCT00038675Not applicableResults posted
• Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDSCompletedNCT00025662Phase 2Results posted
• ABBA CORD: dCBT w/ Abatacept for aGVHD ProphylaxisSuspendedNCT06680661Phase 2
• Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 MutationsSuspendedNCT06630221Phase 2
• A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative NeoplasmWithdrawnNCT06597734Phase 2
• A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMMLTerminatedNCT06563804Phase 1/2
• Non Interventional Study on Iron Toxicity After First Allo-transplant in MDS/CMMLCompletedNCT06267898
• HCT With PTCy in Higher-risk MDSActive, not recruitingNCT06098313Phase 2
• Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic LeukemiaWithdrawnNCT06085638Phase 1/2
• Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.SuspendedNCT06071624Phase 1
• HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD ProphylaxisActive, not recruitingNCT06001385Phase 2
• High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHDWithdrawnNCT05895201Phase 1/2
• A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic LeukemiaActive, not recruitingNCT05883956Phase 3
• Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older PatientsActive, not recruitingNCT05823571Phase 1
• LILRB4 STAR-T Cell Therapy for Monocytic LeukemiaCompletedNCT05739409Not applicable
• A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic MalignanciesCompletedNCT05665530Phase 1
• Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative NeoplasmActive, not recruitingNCT05600894Phase 2
• Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid DiseasesActive, not recruitingNCT05552469Phase 1
• A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDSWithdrawnNCT05456269Phase 1
• A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological MalignanciesActive, not recruitingNCT05428969Phase 1/2
• Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell TransplantsActive, not recruitingNCT05364762Phase 2
• Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid LeukemiaWithdrawnNCT05246384Phase 1/2
• Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)Active, not recruitingNCT05233618Phase 1
• A Study of Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS), or Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)CompletedNCT05218902
• Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.Active, not recruitingNCT05201066Phase 2
• PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell MalignanciesTerminatedNCT05107856Phase 1
• Pharmacokinetics, Tolerability and Safety of NEX-18aCompletedNCT05048498Phase 1
• Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic SyndromesActive, not recruitingNCT05038592Phase 1/2
• Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy with Hypomethylating AgentsCompletedNCT05030675Phase 1
• Inqovi Maintenance Therapy in Myeloid NeoplasmsActive, not recruitingNCT04980404Phase 1
• Calprotectin, a Biomarker of COVID-19 Severity (CALPRO)WithdrawnNCT04953312Not applicable

← Leukemia, Myelomonocytic, Chronic overview